Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects “robust” continuous airway pressure therapy patient growth assisted by growing awareness on obstructive sleep apnea.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed Reports Robust Growth and Innovation in Earnings Call
- Apple, Intel little changed near noon following earnings: Morning Buzz
- Zillow initiated, Electronic Arts upgraded: Wall Street’s top analyst calls
- ResMed upgraded to Buy at UBS as risks skew positive, consensus too cautious
- ResMed price target raised to $247 from $238 at RBC Capital